Last week, NBC’s Today Show giddily announced an exclusive: Privateer Holdings, the Seattle marijuana company long acclaimed locally for its straight, corporate image and Ivy-League-educated bosses, was launching “the first global pot brand” based on the legacy of Bob Marley. The company is likely to start selling pot overseas, says Privateer public-relations director Zack Hutson, previously a spokesperson for Starbucks. “We’re in discussions with a distributor in Israel” – a country with a federally legal medical-marijuana system. Hutson also cites Uruguay and the Netherlands as potential early markets.
Cannabis is the world’s most widely used illicit drug. But for how much longer? In a short space of time we have moved from absolute global prohibition of the drug, with the emergence of legalised and regulated production and retail not in just one nation (Uruguay) but also, surprisingly, in two US states (Colorado and Washington). Do these and other new permissive models in Spain and Belgium, for example, point to a tipping point in the debate? Could cannabis step out of the shadows and join the ranks of alcohol and tobacco, the world’s most popular legal and regulated drugs?
Interview Sebastián Sabini: "Het gaat ons om een totaalaanpak. Legalisering moet samengaan met preventie, met voorlichting en een sterke naleving van de regels. Wiet moet geen commercieel product worden als Coca-Cola, waarvan de reclames je vertrellen dat je er mooi en gelukkig van wordt terwijl het ongezond is. Nederland is een voorbeeld, vooral vanwege de voorlichting. Maar jullie systeem heeft gaten. Omdat de teelt illegaal is."
Cannabis was condemned by the 1961 Single Convention on Narcotic Drugs as a psychoactive drug with “particularly dangerous properties” and hardly any therapeutic value. Ever since, an increasing number of countries have shown discomfort with the treaty regime’s strictures through soft defections, stretching its legal flexibility to sometimes questionable limits.
Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate continues on the decriminalisation, or even legalisation, of drugs, particularly cannabis. Models under development for the legal supply of cannabis are described in this analysis, as well as some of the questions they raise.
Part of the ‘Perspectives on drugs’ (PODs) series, launched alongside the annual European Drug Report, these designed-for-the-web interactive analyses aim to provide deeper insights into a selection of important issues.